Literature DB >> 25475389

Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis.

Jie-Ying Liu1, Yu Yang, Zhi-Zhong Liu, Jian-Jun Xie, Ya-Ping Du, Wei Wang.   

Abstract

The previous, published data on the association between CYP1B1 polymorphisms and cancer risk remained controversial. To derive a more precise estimation of the association between the CYP1B1 polymorphisms and cancer risk, we performed a meta-analysis to investigate the association between cancer susceptibility and CYP1B1 Leu432Val, Asn453Ser, Arg48Gly, and Ala119Ser polymorphisms. For Asn453Ser and Arg48Gly polymorphisms, significantly decreased endometrial cancer was observed among Caucasians. For Ala119Ser polymorphism, we found that individuals with the minor variant genotypes had a high risk of prostate cancer. For Leu432Val polymorphism, we found that individuals with the minor variant genotypes had a higher risk of endometrial cancer and lung cancer and had a lower risk of ovarian cancer. In summary, this meta-analysis suggests that Leu432Val polymorphism is associated with ovarian cancer, lung cancer, and endometrial cancer risk; Asn453Ser and Arg48Gly polymorphisms are associated with endometrial cancer risk among Caucasians, Ala119Ser polymorphism is associated with prostate cancer risk, and Ala119Ser polymorphism is associated with breast cancer risk in Caucasians. In addition, our work also points out the importance of new studies for Ala119Ser polymorphism in endometrial cancer, because high heterogeneity was observed (I (2) > 75 %).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25475389     DOI: 10.1007/s00438-014-0946-x

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   3.291


  144 in total

1.  Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue.

Authors:  Y Ko; J Abel; V Harth; P Bröde; C Antony; S Donat; H P Fischer; M E Ortiz-Pallardo; R Thier; A Sachinidis; H Vetter; H M Bolt; C Herberhold; T Brüning
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

2.  Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer.

Authors:  Mette Sørensen; Herman Autrup; Anne Tjønneland; Kim Overvad; Ole Raaschou-Nielsen
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

3.  Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.

Authors:  Timothy R Rebbeck; Andrea B Troxel; Yiting Wang; Amy H Walker; Saarene Panossian; Stephen Gallagher; Ekaterina G Shatalova; Rebecca Blanchard; Greta Bunin; Angela DeMichele; Stephen C Rubin; Mona Baumgarten; Michelle Berlin; Rita Schinnar; Jesse A Berlin; Brian L Strom
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

4.  Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population.

Authors:  Geyu Liang; Yuepu Pu; Lihong Yin
Journal:  Cancer Lett       Date:  2005-06-08       Impact factor: 8.679

5.  Role of CYP1B1 gene polymorphisms in bladder cancer susceptibility.

Authors:  Antonio S Salinas-Sánchez; María J Donate-Moreno; María-Pilar López-Garrido; José M Giménez-Bachs; Julio Escribano
Journal:  J Urol       Date:  2011-12-16       Impact factor: 7.450

6.  Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.

Authors:  Takahide Fukatsu; Yoshifumi Hirokawa; Tomio Araki; Takuichi Hioki; Tetsuya Murata; Hiroyoshi Suzuki; Tomohiko Ichikawa; Hiromasa Tsukino; Delai Qiu; Takahiko Katoh; Yoshiki Sugimura; Ryuichi Yatani; Taizo Shiraishi; Masatoshi Watanabe
Journal:  Anticancer Res       Date:  2004 Jul-Aug       Impact factor: 2.480

7.  Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk.

Authors:  Tove Rylander-Rudqvist; Sara Wedren; Fredrik Granath; Keith Humphreys; Susanne Ahlberg; Elisabete Weiderpass; Mikael Oscarson; Magnus Ingelman-Sundberg; Ingemar Persson
Journal:  Carcinogenesis       Date:  2003-07-04       Impact factor: 4.944

Review 8.  Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis.

Authors:  Konstantinos P Economopoulos; Theodoros N Sergentanis
Journal:  Breast Cancer Res Treat       Date:  2010-01-07       Impact factor: 4.872

9.  GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population.

Authors:  Rayjean J Hung; Paolo Boffetta; Paul Brennan; Christian Malaveille; Agnès Hautefeuille; Francesco Donato; Umberto Gelatti; Massimiliano Spaliviero; Donatella Placidi; Angela Carta; Antonio Scotto di Carlo; Stefano Porru
Journal:  Int J Cancer       Date:  2004-07-01       Impact factor: 7.396

10.  A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.

Authors:  Shanbeh Zienolddiny; Daniele Campa; Helge Lind; David Ryberg; Vidar Skaug; Lodve B Stangeland; Federico Canzian; Aage Haugen
Journal:  Carcinogenesis       Date:  2008-02-06       Impact factor: 4.944

View more
  8 in total

1.  Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Authors:  Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Robin J Leach; Teresa L Johnson-Pais; Ann W Hsing; Ashraful Hoque; Howard L Parnes; Jeannette M Schenk; Catherine M Tangen; Ian M Thompson; Juergen K V Reichardt; William D Figg
Journal:  Cancer       Date:  2016-05-10       Impact factor: 6.860

2.  Human Microdosing with Carcinogenic Polycyclic Aromatic Hydrocarbons: In Vivo Pharmacokinetics of Dibenzo[def,p]chrysene and Metabolites by UPLC Accelerator Mass Spectrometry.

Authors:  Erin P Madeen; Ted J Ognibene; Richard A Corley; Tammie J McQuistan; Marilyn C Henderson; William M Baird; Graham Bench; Ken W Turteltaub; David E Williams
Journal:  Chem Res Toxicol       Date:  2016-09-09       Impact factor: 3.739

3.  The ovarian carcinoma risk with the polymorphisms of CYP1B1 come from the positive selection.

Authors:  Liying Zhang; Liyuan Feng; Meng Lou; Xihan Deng; Chuanzhong Liu; Li Li
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  Dibenzo[def,p]chrysene transplacental carcinogenesis in wild-type, Cyp1b1 knockout, and CYP1B1 humanized mice.

Authors:  Erin P Madeen; Christiane V Löhr; Hannah You; Lisbeth K Siddens; Sharon K Krueger; Roderick H Dashwood; Frank J Gonzalez; William M Baird; Emily Ho; Lisa Bramer; Katrina M Waters; David E Williams
Journal:  Mol Carcinog       Date:  2016-03-17       Impact factor: 4.784

5.  Hormone-related pathways and risk of breast cancer subtypes in African American women.

Authors:  Stephen A Haddad; Kathryn L Lunetta; Edward A Ruiz-Narváez; Jeannette T Bensen; Chi-Chen Hong; Lara E Sucheston-Campbell; Song Yao; Elisa V Bandera; Lynn Rosenberg; Christopher A Haiman; Melissa A Troester; Christine B Ambrosone; Julie R Palmer
Journal:  Breast Cancer Res Treat       Date:  2015-10-12       Impact factor: 4.872

6.  CYP1B1 G199T Polymorphism Affects Prognosis of NSCLC Patients with the Potential to Be an Indicator and Target for Precise Drug Intervention.

Authors:  Fengzhou Li; Shaofeng Zhang; Qi Zhang; Jinxiu Li; Shilei Zhao; Chundong Gu
Journal:  Biomed Res Int       Date:  2017-03-09       Impact factor: 3.411

7.  Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk.

Authors:  Piera Rizzolo; Valentina Silvestri; Virginia Valentini; Veronica Zelli; Agostino Bucalo; Ines Zanna; Simonetta Bianchi; Maria Grazia Tibiletti; Antonio Russo; Liliana Varesco; Gianluca Tedaldi; Bernardo Bonanni; Jacopo Azzollini; Siranoush Manoukian; Anna Coppa; Giuseppe Giannini; Laura Cortesi; Alessandra Viel; Marco Montagna; Paolo Peterlongo; Paolo Radice; Domenico Palli; Laura Ottini
Journal:  Endocr Connect       Date:  2019-08       Impact factor: 3.335

8.  CYP1B1 as a therapeutic target in cardio-oncology.

Authors:  Alexa N Carrera; Marianne K O Grant; Beshay N Zordoky
Journal:  Clin Sci (Lond)       Date:  2020-11-13       Impact factor: 6.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.